Pressure BioSciences (NASDAQ:PBIO) is featured Monday in an article on industry website BioMed Reports.
An interview with Pressure BioSciences' founder and chief executive Richard Schumacher can be viewed here: http://www.biomedreports.com/2012022790166/video-ceo-of-pressure-biosciences-sees-firms-momentum-continuing-to-build-in-2012.html
The
life sciences company develops and commercializes pressure cycling
technology (PCT) for use in the mass spectrometry market, where end uses
range from forensics, biomarker discovery, to histology and
counter-bioterror applications.
The technology uses rapid cycles
of hydrostatic pressure to control biomolecular interactions, allowing
for a high degree of precision, speed and reproducibility, the company
said.
Earlier this month, Pressure BioSciences closed on an $800,000 private placement financing.
The
placement consisted of the sale of 971,867 shares of restricted common
stock, and 485,937 warrants to purchase further common stock.
Last month, the life sciences company saw its shares surge after it
announced the signing of a co-marketing and selling agreement with
Digilab, expected to boost its sales efforts significantly.
The companies said they intend to co-market and sell their respective
product lines worldwide, including in industry publications, at
scientific meetings, on each company's website, through common
collaborator studies, at key industry trade shows, and in visits to
customer sites.
Proactiveinvestors is a leading multi-media news organisation, investor portal and events management business with offices in New York, Sydney, Toronto, Frankfurt and London.
No comments:
Post a Comment